文献速递免疫规划卫生政策与健康促进

流感疫苗选择的经济学效益在美国各地是否不同?一项基于智能体的建模研究

Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study.
PubMed 文献 · Vaccine · 2017-06-09

该研究基于智能体建模,在五个代表人口年龄分布极端的美国县中比较四种流感疫苗选择策略(无选择、儿童选择、成人选择、两个年龄组均选择)的公共卫生影响与成本效果。结果显示,在中等流感传染性假设下,两个年龄组均选择的策略在全部五个县中避免病例数最高,且为优势策略;敏感性分析支持这一基础病例发现。

要点

  • 两个年龄组均提供选择在五个县中避免病例数最高,且为成本节约的优势策略。
  • 疫苗选择使流感疫苗接种覆盖率从CDC数据基础上提高6.5%(范围3.25%-11.25%)。
  • 敏感性分析改变流感传染性、成本和疫苗覆盖率提升程度,均支持基础病例发现。

核心结论

  • 提供免针头流感疫苗选择有潜力显著减轻流感疾病负担并节约成本,且在不同人群中结果一致。

研究设计与样本

  • 基于智能体的建模研究,模拟五个被选为代表人口年龄分布极端的美国县中个体互动与流感传播。
  • 比较四种策略:无选择、儿童选择、成人选择、两个年龄组均选择。
  • 选择方案为肌内注射灭活流感疫苗(IIV-IM)或年龄适宜的免针头疫苗(鼻喷LAIV或皮内IIV-ID)。
  • 流感疫苗接种覆盖率取自美国疾病控制与预防中心(CDC)数据,并提高6.5%(范围3.25%-11.25%)以反映疫苗选择的效果。

主要发现

  • 在中等流感传染性假设下,两个年龄组均选择策略在全部五个县中避免病例数最高,尽管人口特征不同。
  • 成本效果分析中,两个年龄组均选择策略为优势策略。
  • 敏感性分析改变流感传染性、成本和因选择导致的疫苗覆盖率提升程度,均支持基础病例发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a prior agent-based modeling study, offering a choice of influenza vaccine type was shown to be cost-effective when the simulated population represented the large, Washington DC metropolitan area. This study calculated the public health impact and cost-effectiveness of the same four strategies: No Choice, Pediatric Choice, Adult Choice, or Choice for Both Age Groups in five United States (U.S.) counties selected to represent extremes in population age distribution. METHODS: The choice offered was either inactivated influenza vaccine delivered intramuscularly with a needle (IIV-IM) or an age-appropriate needle-sparing vaccine, specifically, the nasal spray (LAIV) or intradermal (IIV-ID) delivery system. Using agent-based modeling, individuals were simulated as they interacted with others, and influenza was tracked as it spread through each population. Influenza vaccination coverage derived from Centers for Disease Control and Prevention (CDC) data, was increased by 6.5% (range 3.25%-11.25%) to reflect the effects of vaccine choice. RESULTS: Assuming moderate influenza infectivity, the number of averted cases was highest for the Choice for Both Age Groups in all five counties despite differing demographic profiles. In a cost-effectiveness analysis, Choice for Both Age Groups was the dominant strategy. Sensitivity analyses varying influenza infectivity, costs, and degrees of vaccine coverage increase due to choice, supported the base case findings. CONCLUSION: Offering a choice to receive a needle-sparing influenza vaccine has the potential to significantly reduce influenza disease burden and to be cost saving. Consistent findings across diverse populations confirmed these findings.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. DePasse JV, Nowalk MP, Smith KJ, et al. Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study. Vaccine. 2017. PMID: 28606814. doi:10.1016/j.vaccine.2017.05.093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。